Veracyte has an employee rating of 3.5 out of 5 stars, based on 116 company reviews on Glassdoor which indicates that most employees have a good working experience there.
Compensation is pretty good overall. Products really are disruptive, so if you can sell there is opportunity. Good training program sets new reps up for success. RSUs for new hires that have some significant upside. Still relatively new company with room to grow your career
Cons
Having multiple products in the pulmonary space during COVID lead to a huge sales staff reduction, and many reps were terminated including some tenured reps.
Veracyte Response
5y
Thanks for taking the time to provide your perspective. We’re very pleased to hear that you felt positively about our training, compensation and products. We were immensely saddened this summer when COVID-19 related factors forced us to re-structure our field organization. Thanks again for providing your input.
Corporate and (some) management needs work. Company went downhill when certain people took over new roles. A great culture is gone.
Veracyte Response
5y
Thanks for your constructive feedback. Maintaining a positive corporate culture is a priority for us, so we are disappointed to hear that you feel our culture has changed. The Veracyte sales team and leadership have expanded over the past couple of years to meet the needs of our business and customers. We recently announced a new general manager-based structure to advance our growing roster of genomic tests and support our global expansion. We believe this new GM-based structure will enable us to best serve our customers around the world and empower our leaders and employees throughout the organization.
Growth company, great compensation, work-life balance
Cons
Growing pains, turnover in management
Veracyte Response
5y
Thanks for sharing your insights on your Veracyte experience. We’re particularly pleased to hear that you experienced great work-life balance during your time with us. Veracyte is undergoing exciting growth, including our transformation into a global diagnostics company, our growing menu of genomic tests in a range of diseases, and our planned launch next year of four new products. We appreciate that there are growing pains in this journey and we are actively working to implement new structure and programs to manage these changes. Thanks again for taking time to provide your perspective.